ANTIMICROBIAL ACTIVITY OF CS-940, A NEW TRIFLUORINATED QUINOLONE

The antimicrobial activity of CS-940, a new trifluorinated quinolone drug, was tested against 761 clinical isolates. CS-940 activity against members of the family Enterobacteriaceae was most similar to that of ciprofloxacin and ofloxacin, with a range of MICs inhibiting 90% of isolates tested (MIC(90)s) of 0.015 to 16 mu g/ml (median MIC(90), 0.06 mu g/ml). CS-940 had greater activity than ciprofloxacin or ofloxacin when they were tested against Acinetobacter spp, (MIC(90)s, 0.03 mu g/ml) and Stenotrophomonas (Xanthomonas) maltophilia (MIC(90)s, 2 mu g/ml). CS-940 demonstrated a high degree of potency against Haemophilus influenzae, Moraxella catarrhallis, and Neisseria spp. (MIC(90)s, 0.06 mu g/ml). CS-940 was two- to eightfold more active than ciprofloxacin or ofloxacin against oxacillin-susceptible Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, and coagulase-negative Staphylococcus spp. CS-940 was also very active against Streptococcus spp, and enterococci, for which MIC(90)s were less than or equal to 2 mu g/ml; for Enterococcus faecium, however, the MIC(90) was 4 mu g/ml. CS-940 was generally less active thana comparison investigational fluoroquinolone, clinafloxacin. This compound appears promising by in vitro test analysis and warrants further in vivo trials.